PROGETTO FORMATIVO

II° European Symposium on Rare and genetic Cardiovasculas Diseases

The Patient's clinical pathway in inherited and rare disease: a journey toward precision medicine

➥ *Organizing & Logistic Secretariat*	SUMMEET SRL – ID 604
➥*Dates:*	05th – 06th -07th December 2023
➥*Venue*:	***Hotel Royal Continental*** *Via Partenope 38/44* *80121 - Napoli*
➥*Type*:	*In presence – NO ECM*
➥*Objective*:	*Provide an update to learners on emerging topics, acquire theoretical and practical knowledge on recent innovations, motivate the patient to continue with the therapy and make him aware of the high risk involved in not continuing or starting it*
➥*Scientific Coordinators:*	***Perry M. Elliott*** ***G. Limongelli***
➥*Participants:*	N. 120 Participants (Categories: Cardiology, Endocrinology, Metabolic Diseases and Diabetology, Internal Medicine, General Medicine)
➥*Duration (H/Days)*:	N° 3 Days

RAZIONALE SCIENTIFICO

On behalf of the Scientific Committee it is a great pleasure to welcome you to the city of Naples for the xth International Meeting on Inherited and Rare Cardiovascular Disorders, 2023.

Inherited and rare cardiovascular diseases comprise a group of more than 50 diseases, including primary arrhythmia disorders, malformation syndromes, cardiomyopathies, connective tissue disorders, congenital heart defects and metabolic diseases. Taken together, these disorders may affect up to 1 in 240 individuals and are a significant burden on healthcare services.

For much of the history of medicine, patients suffering from rare diseases have found themselves to be beyond hope, but in recent years, disease awareness has spread around the world and the advances in molecular genomics have facilitated personalised therapeutic management of patients with rare and ultra-rare disorders according to their specific phenotype.

The importance of rare cardiovascular disorders is reflected by recent efforts of national healthcare agencies to reduce diagnostic delay among patients with rare diseases, through the institution of disease-specific "patient pathways". Fundamental to this effort is a multidisciplinary and collaborative approach between healthcare agencies, hospitals and healthcare providers.

The aim of this meeting is to improve the education of cardiologists and other specialists in the field of rare and genetic diseases and to highlight recent advances in inherited cardiovascular disease, with a particular focus on new approaches to diagnosis and management.

We are enormously fortunate to have some of the World's greatest experts in our faculty and sincerely wish you a successful and enjoyable meeting.

SCIENTIFIC PROGRAMME
Day One – 05 december 2023

10.00 Meeting Opening: European, National & Regional Key Figures

10.30 Introduction

10.45 Round Table. European, National & Regional Rare Disease Networks. Where are we now? We are we going? (ICoN, ERN, EU).

11.45 *Coffee break*

12.30 Lecture (European Reference Network): Prevention of Sudden Cardiac Death in Europe

13.00 Lecture: Undiagnosed Disease (Local)

13.30 Conclusion & Lunch

INTERNATIONAL CARDIOMYOPATHY NETWORK–LAUNCH OF POLICY MANIFESTO

16.00 Introduction

16.10 Why do we need a strategy?

16.40 Raising the patient voice

17.10 The need for multidisciplinary Networks

17.40 Bridging the gap between science and clinical cardiology

18.10 ICoN: The Agenda for Change

18.40 Conclusion

SCIENTIFIC PROGRAMME
Day Two – 06 december 2023

8.00 Registration

8.45 Welcome and opening remarks

SESSION ONE: HEART MUSCLE DISEASE

NEW GUIDELINES FOR CARDIOMYOPATHIES

9.00 How the new Guidelines will change diagnosis and practice in CMPs?

9.20 How the new Guidelines will change the approach towards risk assessment?

9.40 Time for a molecular classification

HYPERTROPHIC CARDIOMYOPATHY

10.00 Risk stratification in HCM: Not just sudden death

10.15 Managing LVOTO: from surgery to myosin inhibitors

10.30 Heart failure: the new frontier in HCM

10.45 Discussion Coordinator

11.00 Coffee break

DILATED CARDIOMYOPATHY

11.30 Genotype and phenotype in DCM: From one to many diseases

11.45 Non dilated hypokinetc cardiomyopathy: putting the name in the context

12.00 The future of precision medicine in dilated cardiomyopathy

12.15 Discussion Coordinator

ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY

12.30 Correlating genotypes with disease: clinical & molecular classification of ARVC

12.45 The impact of multimodality imaging on the diagnosis of ACM

13.00 Advances in risk assessment and the management of ventricular arrhythmias

13.15 Discussion Coordinator

13.30 Lunch

MYOCARDITIS AND INFLAMMATORY DISEASES

14.30 When to perform genetic testing in myocarditis?

14.45 When to perform endomyocardial biopsy in myocarditis?

15.00 Diagnosis and management of cardiac sarcoidosis

15.15 Discussion Coordinator

STORAGE, INFILTRATIVE, NEUROMUSCULAR DISORDERS

15.30 Cardiac Amyloidosis: diagnosis and natural history

15.45 Fabry Disease: the importance of registries and networks

16.00 Neuromuscular Disease and the Heart

16.15 Discussion Coordinator

16.30 Coffee break

PAEDIATRIC HEART FAILURE & CARDIOMYOPATHIES

17.00 Etiology and clinical presentation in children

17.15 Risk prediction of outcome in children with Cardiomyopathies

17.30 Novel therapeutic approaches in childhood heart failure and Cardiomyopathies

17.45 Discussion Coordinator

18.15 Conclusions

SCIENTIFIC PROGRAMME
Day Three – 07 december 2023

8.30 Introduction

8.35 Lecture: What is a cardiomyopathy in 2023?

SESSION TWO: GENE THERAPY

9.00 Video

GENE THERAPY IN RARE DISEASES

9.15 New Therapeutic approaches for transthyretin cardiac amyloidosis

9.30 New therapeutic approaches for Cardiomyopathies

9.45 Gene Therapy for Ion Channel Disease

10.00 Gene Therapy in muscular dystrophies

10.15 Discussion Coordinator

SESSIONE THREE: FUTURE RESEARCHERS

New FRONTIERS in CARDIOMYOPATHY RESEARCH

10.30 Spain?

10.45 UCL Team?

11.00 Naples Team?

11.15 Olivotto/Biagini team?

11.30 Discussion Coordinator

11.45 Coffee break

SESSIONE FOUR: HEART RHYTHM

MOLECULAR AUTOPSY & FAMILY SCREENING IN SUDDEN ADULT DEATH SYNDROME

12.15 Sudden cardiac death prevention: a public health priority

12.30 The emerging role of molecular autopsy

12.45 How to identify and manage family members at risk?

13.00 Discussion Coordinator

13.30 Lunch

SESSIONE FIVE: VESSELS

FAMILIAL DYSLIPIDAEMIAS

14.30 Familiar hypercholesterolaemia: diagnosis and management

14.45 Familiar dysbetalipoproteinaemia: diagnosis and management

15.00 Genetic causes of hypertriglyceridemia: diagnosis and management

15.15 Discussion Coordinator

15.30 Coffee Break

GENETIC AORTOPATHIES

16.00 Marfan syndrome and inherited aortopathies

16.15 Non-syndromic aortopathies

16.30 Genetics in bicuspid aortic valve

16.45 Discussion Coordinator

17.15 Conclusions & Final Remarks